About Us

We are building and advancing a portfolio through global approval by establishing strong ties and collaborations with endocrinologists, the medical community at large and patient advocacy organizations worldwide.

Our goal is to provide physicians with new therapeutic strategies to improve the lives of their patients with rare endocrine and metabolic disease. Currently, our pipeline includes two therapeutic peptides, AZP-3601, for the treatment of hypoparathyroidism, and AZP-3404 which is currently undergoing clinical indication prioritization work.

Our global management team is composed of a highly dedicated group of senior executives with proven drug development expertise and achievements in peptide therapeutics, as well as thorough knowledge of rare endocrine and metabolic disorders.

We are supported by an impressive board of directors and strong international syndicate of investors, as well as a robust IP portfolio and key academic collaborations.

LEADERSHIP

Management

Our global management team is composed of a highly dedicated group of senior executives with proven drug development expertise and achievements in peptide therapeutics, as well as thorough knowledge of rare endocrine and metabolic disorders.

Thiery Abribat
Thierry Abribat, Ph.D.

Founder and Chief Executive Officer

Michael Culler
Michael Culler, Ph.D.

Chief Scientific Officer

Soraya Allas
Soraya Allas, M.D., PH.D.

VP, Clinical Development and Regulatory Affairs

Patrick Loustau
Patrick Loustau, M.S., M.A.

Chief Business Officer

Thomas Delale, Ph.D.
Thomas Delale, Ph.D.

VP, Portfolio Management

Delphine Martinez
Delphine Martinez

General Counsel

David Duracher, Ph.D.

VP Chemistry Manufacturing and Control

Bénédicte Gagnere
Bénédicte Gagnere, M.S.

Head of Finance

Board OF DIRECTORS
Pierre Legault

Chairman of the Board of Directors

Felice Verduyn-van Weegen

Investment Manager at LSP

Naveed Siddiqi

Partner at Novo Ventures

Thierry Laugel

Managing Partner at Kurma Partners

Roy Amariglio

Principal at OrbiMed

Iyona Rajkomar

Partner at Pontifax

Thierry Abribat

CEO of Amolyt Pharma

Michael Culler

CSO of Amolyt Pharma

Observers
René Kuijten

Managing Partner at LSP

Meredith Fisher

Partner at Partners Healthcare Innovation Fund

OlivIer Martinez

Senior Investment Director at Bpifrance

Mounia Chaoui

Associate Director at Turenne Santé

Investors

Since its inception, Alizé Pharma 3, now Amolyt Pharma, has raised 3.3 M€ ($3.6 M) in seed funding, followed by a 67 M€ ($75 M) Series A financing from a strong international syndicate of investors.

Scientific and Medical Advisors
David Clemmons
David Clemmons, M.D.

University of North Carolina

Aart Jan (AJ) Van Der Lely, M.D., Ph.D.
Aart Jan (AJ) van der Lely, M.D., Ph.D.

Erasmus University Medical Center

AZP-3601: Clinical Advisory Board
JOHN BILEZIKIAN
John Bilezikian, M.D.

College of Physicians & Surgeons, Columbia University

MARIA LUISA BRANDI
Maria Luisa Brandi, M.D.

University of Florence

Aliya Khan, M.D.
Aliya Khan, M.D.

McMaster University

Michael Mannstadt
Michael Mannstadt, M.D.

Massachusetts General Hospital and Harvard Medical School

Lars Rejnmark, M.D.
Lars Rejnmark, M.D.

Aarhus University

Scroll to Top